Abstract 466P
Background
Extracellular matrix (ECM) plays a key role in tumorigenesis and progression. Collagen XII, expressed by the COL12A1 gene, is an important component of the ECM. COL12A1 is associated with tumorigenesis and poor prognosis in several cancers, but its role in breast cancer (BC) is unclear, especially the different expression between primary and metastasic foci of BC has not been reported.
Methods
We analyzed the expression of COL12A1 in tumor tissue and normal tissue, plotted a Kaplan-Meier curve by GEPIA, and analyzed mutation by COSMIC and cBioPortal in BC. PPI, GGI and pathway and process enrichment analysis were performed by STRING and Metascape. GeneMANIA was used to map gene interaction networks. BC cases with paired primary and metastatic foci were found out from TCGA database for analyzing different expression of COL12A1 in primary and metastatic foci. Immunohistochemical (IHC) staining was performed in paraffin tissue samples of paired primary lesion and lung metastases from triple-negative breast cancer (TNBC) patients.
Results
The results showed that COL12A1 in BC tissues was upregulated and was associated with poor prognosis of BC and the Luminal A+Luminal B subgroup. 3.04% of BC patients had COL12A1 gene alteration. Missense substitution (37.59%) was the most frequent mutation type. Among the 10 related genes, COL3A1, COL5A2, MMP12, P4HA1, P4HA2, P4HA3 and SERPINH1 were significantly upregulated in tumor tissue. The 20 most relevant genes in the GGI network are COL11A1, ID1, COL8A1, MMP9, COL5A1, MMP2, ISLR, LUM, COL7A1, COL3A1, COL1A2, MMP3, COL10A1, COL6A1, COL11A2, COL8A2, MMP8, MMP12. SERPINH1 and MMP13, which are enriched in several pathways including collagen degradation, collagen formation, collagen metabolic process, endodermal cell differentiation, collagen fibril organization and so on. Furthermore, analysis of paired cases from the TCGA-BRCA database revealed that COL12A1 was expressed with higher level in primary foci than metastatic foci. IHC staining revealed that the expression of COL12A1 was upregulated in primary foci of TNBC.
Conclusions
In conclusion, COL12A1 may be a poor prognostic predictor and a specific therapeutic target for primary foci in BC, especially in TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Science and Technology Developing Projects (SKYD2022083, SYSD2020079 and SYSD2020075).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
Presenter: Lixi Li
Session: Poster session 04
448P - Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
Presenter: Hossameldin Abdallah
Session: Poster session 04
449P - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Presenter: Claudia von Arx
Session: Poster session 04
450P - A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
Presenter: Ying Zhang
Session: Poster session 04
451P - Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Presenter: Beatriz Gosalbez Pequeno
Session: Poster session 04
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Presenter: Xiaojia Wang
Session: Poster session 04
453P - Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Presenter: Jinmei Zhou
Session: Poster session 04
454P - Real-world genomic profiling of patients with advanced or metastatic triple-negative breast cancer in the UK and EU4: A systematic literature review
Presenter: Barinder Singh
Session: Poster session 04
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Presenter: Raffaella Palumbo
Session: Poster session 04